Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of Cultured Autologous BMSCs for Decompensated Liver Cirrhosis
NCT02327832Phase 1Unknown
- Sponsor
- Yamaguchi University Hospital
- Start
- Dec 2014
- Primary completion
- Mar 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous bone marrow derived mesenchymal stromal cells in Liver cirrhosis (LC), sponsored by Yamaguchi University Hospital. Primary endpoint: Incidence of adverse events at 24 weeks. Status: unknown.
02
Drugs
autologous bone marrow derived mesenchymal stromal cells
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT02327832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02327832.